Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: coronavirus neutralising antibodies - AbCellera/Eli Lilly and Company

Drug Profile

Research programme: coronavirus neutralising antibodies - AbCellera/Eli Lilly and Company

Alternative Names: coronavirus (2019-nCoV) neutralising antibodies - AbCellera/Eli Lilly and Company; SARS-CoV-2-neutralizing antibodies - AbCellera/Eli Lilly and Company

Latest Information Update: 30 Mar 2020

At a glance

  • Originator Abcellera; Eli Lilly and Company
  • Developer Abcellera; Eli Lilly and Company; National Institute of Allergy and Infectious Diseases
  • Class Antibodies; Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 12 Mar 2020 Abcellera and Eli lilly and Company agree co-develop Coronavirus neutralizing antibodies in Canada for COVID-19 infections
  • 29 Jan 2020 Early research in COVID-2019-infections (Prevention) in Canada (Parenteral)
  • 29 Jan 2020 Early research in COVID-2019-infections in Canada (Parenteral)

Development Overview

Introduction

Antibody therapeutics are being co-developed by AbCellera and Eli lilly and Company in collaboration with National Institute of Allergy and Infectious Diseases using pandemic response platform, for the prophylaxis and treatment of COVID-2019 infections. The technology is a microfluidic platform that uses miniaturised assays to screen antibodies from individual B cells from any species, including directly from human patients. These proprietary assays can be customised to screen for specific therapeutic properties, depending on the disease target or application. Early research is underway in the Canada.

LY CoV555 [See Adis Insight drug profile 800058899] has advanced from this research programme for coronavirus neutralising antibodies by Eli Lilly and AbCellera.

Company Agreements

In March 2020, Abcellera and Eli Lilly entered into a research and development agreement to develop antibodies for up to nine Eli Lilly-selected therapeutic targets. One of therapeutic targets is for treatment and prevention of COVID-19 infections, caused by SARS-CoV-2 coronavirus. Eli Lilly will select up to eight additional targets during the multi-year agreement. Abcellera's rapid pandemic response platform developed under the DARPA Pandemic Prevention Platform (P3) programme will be used in this collaboration along with Eli lilly's rapid development, manufacturing and distribution of therapeutic antibodies. Under the terms of agreement Abcellera and Eli lilly will together fund the initial development cost of the product, after which Eli lilly will be responsible for all further development, manufacturing and distribution. Eli lilly has paid AbCellera an up-front payment and will pay preclinical, clinical, and commercial milestones and tiered royalties on future sales. [1] [2]

Key Development Milestones

Financing information

In May 2020, Abcellera received fund worth of $175.6 million from the Government of Canada. The fund was allocated under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to support and expand the discovery of antibodies for the prophylaxis and treatment of COVID-2019 infections, and to build technology and manufacturing infrastructure for the antibody therapies [3] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antibodies, Antivirals
  • Mechanism of Action Immunomodulators
  • WHO ATC code

    J05 (Antivirals for Systemic Use)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research Canada Parenteral / unspecified Abcellera, National Institute of Allergy and Infectious Diseases, Eli Lilly and Company 29 Jan 2020
COVID 2019 infections - - Research Canada Parenteral / unspecified Abcellera, National Institute of Allergy and Infectious Diseases, Eli Lilly and Company 29 Jan 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Abcellera Originator Canada
Eli Lilly and Company Originator USA
Eli Lilly and Company Owner USA
Abcellera Owner Canada
National Institute of Allergy and Infectious Diseases Collaborator USA

Development History

Event Date Update Type Comment
12 Mar 2020 Licensing Status Abcellera and Eli lilly and Company agree co-develop Coronavirus neutralizing antibodies in Canada for COVID-19 infections [1] Updated 30 Mar 2020
29 Jan 2020 Phase Change Early research in COVID-2019-infections (Prevention) in Canada (Parenteral) Updated 07 Feb 2020
29 Jan 2020 Phase Change Early research in COVID-2019-infections in Canada (Parenteral) Updated 03 Feb 2020

References

  1. AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19.

    Media Release
  2. AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly.

    Media Release
  3. AbCellera Receives $175.6 Million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs.

    Media Release
Back to top